On October 26, 2026, CHUANG'S INT'L (00367.HK) said it had exchanged US$3.5 million of 5.95% China SCE notes for about US$1.4 million of new 2.00% notes, about US$1.6 million of mandatory convertible bonds and about 2.6 million shares, with no cash consideration.
On 26 October 2026, PACIFIC BASIN (02343.HK) said Kristian Helt will step down as executive director on 21 November 2026, remaining head of chartering.
On October 26, 2026, the HSI rose 0.51% as the HSTECH fell 0.37%. BAIGE DIGITAL led Stock Connect gainers, up 27.81%, on HK$2.075 billion of southbound selling.
On 26 October 2026, HENGRUI PHARMA (01276.HK) won a clinical trial approval for SHR-2005 with SHR-1501, with or without adebrelimab, in bladder cancer.
On October 26, 2026, LEPU BIO (02157.HK) reported ESMO data showing CMG901's Phase III trial met its primary endpoint, with median OS of 10.0 versus 5.0 months in third-line or later CLDN18.2-positive gastroesophageal cancer.
On October 26, 2026, HUTCHMED (00013.HK) reported SANOVO Phase III data showing ORPATHYS® plus TAGRISSO® extended median PFS to 24.9 months versus 13.8 months in first-line EGFR-mutant, MET-overexpressed NSCLC, cutting progression risk 44%.
On October 26, 2026, the SFC said 22 shareholders and related parties of NEW GONOW RV (00805.HK) held 41.69% and chairman Miao Xuezhong 48.69%, taking the combined stake to 90.38%.
On 26 October 2026, TENNOR THERAP-B (06872.HK) proposed an H share buyback of up to 5,232,892 shares, or 10% of issued H shares, for up to RMB 50 million.
On October 26, 2026, GLORY SUN LAND (00299.HK) said the Listing Committee decided to cancel its listing under Rule 6.01A(1); absent a review, the last trading day is November 6 and delisting takes effect on November 9.
On October 26, 2026, YUE YUEN IND (00551.HK) issued a profit warning, expecting nine-month profit attributable to owners to fall about 50%-55% from US$278.7 million a year earlier, with manufacturing revenue down 3.8%.
On 26 October 2026, CH AGRI-PROD EX (00149.HK) issued HKD 20 million of 2038 notes under its HKD 1 billion medium term note programme, due 26 October 2038.
On 26 October 2026, ELIFE HLDGS (00223.HK) completed a placing of 277,520,000 shares at HKD 0.1 each, raising net proceeds of about HKD 27.20 million.
On October 26, Hong Kong stocks traded mixed, the Hang Seng Index up 0.51% on turnover of 175.8 billion HKD and southbound net selling of 2.275 billion HKD.
BUTONG GROUP (06090.HK) listed on the Main Board of the Hong Kong Stock Exchange on 23 September 2025 at a final offer price of HKD 71.20. Founder Wang Wei established the Boyan Family Trust and serves as its settlor and protector, while co-founder Shen Ling established the Shen Ling Family Trust and serves as its settlor and protector; the trustee of both trusts is Vistra Trust (Singapore) Pte. Limited of Singapore. The company was included in the Hang Seng Composite Index and added to the Stock Connect eligible securities lists on 9 March 2026.
On Oct 23, HBM Holdings-B (02142.HK) announced that batoclimab injection (Enlida) has been approved by China's NMPA for generalized myasthenia gravis, the company's first approved product, on which it retains tiered royalties in Greater China. Included in the Stock Connect on Sept 7, its southbound stake rose from 2.10% on the first effective day to 13.24% on Oct 23, or 119.81 million shares worth about HK$1.23 billion.
LC HOLDING (02490.HK) fell 0.36% to HKD 4.140 on Oct 26; Liu Family Trust holds shares via Lecang Flourishing; Trident Trust at 32.60%; interim profit up 42.9%.
